SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech binary events

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (40)6/4/2003 1:13:10 AM
From: Miljenko Zuanic  Read Replies (1) of 295
 
Trial by itself is strange. Mono-therapy, randomized (1:1) double-blind placebo-controlled for metastatic progressive RCC?

Are all this patients following protocol? Or did they followed protocol?
What chance do you have with this type of cancer on placebo? If all survival are on Neovastat and none on placebo, than 18 months after last pts enrolled we still do not have median survival time. This will be much better than 16 months in PI/II. To achieve this type of the results majority of subject should be in remission, or long term non-progressed stable disease. Can placebo do this for 40-50 subjects out of 150? Miracle?

Very interesting!!!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext